GlycoMimetics Stockholders Approve Merger with Crescent Biopharma

An announcement from GlycoMimetics ( (GLYC) ) is now available.

On June 5, 2025, GlycoMimetics announced that its stockholders approved a proposed merger with Crescent Biopharma, Inc., along with all related proposals during a special meeting. The merger includes a reverse stock split of GlycoMimetics’ common stock at a ratio of 1-for-100, which will reduce the number of outstanding shares significantly. Following the merger, the combined company will trade under the name Crescent Biopharma, Inc. on the Nasdaq Capital Market. This strategic move is expected to enhance GlycoMimetics’ market positioning and operational capabilities, impacting stakeholders by potentially increasing the company’s market value and operational scope.

The most recent analyst rating on (GLYC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on GlycoMimetics stock, see the GLYC Stock Forecast page.

Spark’s Take on GLYC Stock

According to Spark, TipRanks’ AI Analyst, GLYC is a Underperform.

GlycoMimetics is facing major financial hurdles with a lack of revenue and ongoing losses, placing substantial risk on its operations. The recent negative corporate events add to the uncertainty and challenge investor confidence. Despite some short-term technical momentum, the overall outlook is weak due to the absence of profitability and unattractive valuation metrics.

To see Spark’s full report on GLYC stock, click here.

More about GlycoMimetics

GlycoMimetics is a late clinical-stage biotechnology company that was focused on discovering and developing glycobiology-based therapies for cancers, including AML, and inflammatory diseases. The company aimed to develop transformative therapies for diseases with high unmet medical needs using its specialized chemistry platform to create small molecule drugs known as glycomimetics.

Average Trading Volume: 794,370

Technical Sentiment Signal: Sell

Current Market Cap: $13.55M

For an in-depth examination of GLYC stock, go to TipRanks’ Stock Analysis page.